Previous Close | 0.2932 |
Open | 0.3355 |
Bid | 0.3155 x 5800 |
Ask | 0.3189 x 5800 |
Day's Range | 0.2735 - 0.3600 |
52 Week Range | 0.0510 - 1.2200 |
Volume | |
Avg. Volume | 65,979,558 |
Market Cap | 91.337M |
Beta (5Y Monthly) | 1.38 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7900 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.60 |
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failure Proof-of-concept studies of crofelemer ...
Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called "chemo mouth") in Q3 2024 Company to feature "Make Cancer Less Shitty" patient advocacy program at ONS Congress SAN FRANCISCO, CA ...
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect ...